Biologics litigation, the first cases under the new PMNOC Regulations, the first Certificates of Supplementary Protection issued (and the first rejection!), patent prosecution developments and Galderma headed to the FCA : 2018 has been an exciting year in Canadian pharmaceutical law so far. Join IPIC’s Life Science Subcommittee for all the latest and greatest on these topics and more.
![](ajax/?comaction=thumbnail&sizex=230&file=5d0145832bc7a.jpg)
Melanie Szweras
Bereskin & Parr LLP
![](ajax/?comaction=thumbnail&sizex=230&file=5d0145e986716.jpg)
Andrew Skodyn
Blake, Cassels & Graydon LLP
![](ajax/?comaction=thumbnail&sizex=230&file=5d014625c40f0.jpg)
Mee Ling Wong
Wilson Lue LLP
![](ajax/?comaction=thumbnail&sizex=230&file=5d0146502d011.jpg)
Emily Kettel
Bennett Jones LLP